Two stocks in Healthcare
GSK vs Oxford Biomedica: profit, growth, debt and price compared
GSK is stronger on 4 of 6 figures: profit margin, debt, price for its expected profit and price trend. Oxford Biomedica is stronger on 2: sales growth and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GSKGSK.L | Oxford BiomedicaOXB.L | |
|---|---|---|
| Net margin | Stronger: 13.0% | −23.2% |
| Revenue growth, past year | +4.00% | Stronger: +9.00% |
| Debt to equity | Stronger: 129.6% | 273.1% |
| Forward P/E | Stronger: 9.9× | Loss |
| Dividend yield | 3.64% | — |
| Analysts | Hold · 21 | Stronger: Buy · 8 |
| From its 200-day average | Stronger: −0.8% | −5.2% |
Share price over the past year
- GSK+5.5%
- Oxford Biomedica−13.2%
20 Nov 202518 Nov 2026
GSK or Oxford Biomedica: which is stronger?
- GSK.L
Which is more profitable?
GSK keeps more of each sale as profit: 13.0% against −23.2%.
- OXB.L
Which is growing its sales faster?
Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +4.00%.
- GSK.L
Which has borrowed less?
GSK has borrowed less: its debt is 129.6% of what its shareholders own, against 273.1% for Oxford Biomedica.
- GSK.L
Which costs less for the profit it is expected to make?
GSK is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.
Which pays more in dividends?
GSK pays 3.64% a year in dividends for what a share costs, where Oxford Biomedica pays none.
- OXB.L
Which do analysts rate higher?
Analysts are warmer on Oxford Biomedica: Buy, against Hold for GSK.
- GSK.L
Which is in the stronger price trend?
GSK's price is in the stronger trend: 0.8% below its 200-day average, against 5.2% below.
What each company does
GSK.LGSK
GSK plc, together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Reports results on 3 February 2027
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.